Ionis Pharmaceuticals IONS Sapablursen — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
In the second quarter of 2026, we earned a $20 million milestone payment when Ono initiated a pivotal clinical trial for sapablursen under this collaboration. We recognized this milestone payment as R&D revenue in full in the second quarter of 2026 because we did not have any remaining performance obligations related to the milestone payment. We will achieve the next payment of $15 million if the FDA accepts a New Drug Application, or NDA, filing for sapablursen in the U.S. From inception through June 30, 2026, we have received more than $305 million in payments from Ono.
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's sapablursen — revenue?
- Ionis Pharmaceuticals (IONS) reported sapablursen — revenue of $20M in Q2 2026.
- What does sapablursen — revenue mean?
- This metric represents the net revenue recognized from the sale or licensing of the specific pharmaceutical product or therapeutic candidate identified as Sapablursen. It reflects the economic value generated from commercial activities or contractual arrangements, excluding any taxes collected from customers. This figure is a key indicator of the product's market adoption, commercial success, and contribution to the company's overall top-line performance.
Ask your AI about Ionis Pharmaceuticals's sapablursen — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
